ArticleCancer research2006
Sustained expression of early growth response protein-1 blocks angiogenesis and tumor growth.
Article in Cancer research, 2006. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 31 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
31 citing papers in PubMed, 64 citations in OpenAlex.
- Multifaceted regulatory mechanisms of the EGR family in tumours and prospects for therapeutic applications (Review).International journal of molecular medicine · 2025Review
- The Role of the Transcription Factor EGR1 in Cancer.Frontiers in oncology · 2021Review
- Ectopic Overexpression of Coiled-Coil Domain Containing 110 Delays G2/M Entry in U2-OS Cells.Development & reproduction · 2020Article
- Friend or foe, the role of EGR-1 in cancer.Medical oncology (Northwood, London, England) · 2019Review
- Article
- Evaluation of therapeutic effects ofOncology letters · 2018Article
- Regulation of Tumor Progression by Programmed Necrosis.Oxidative medicine and cellular longevity · 2018Review
- Human cytomegalovirus infection downregulates vitamin-D receptor in mammalian cells.The Journal of steroid biochemistry and molecular biology · 2017Article
- Calcium-sensing receptor silencing in colorectal cancer is associated with promoter hypermethylation and loss of acetylation on histone 3.International journal of cancer · 2014Article
- Role of proinflammatory cytokines on expression of vitamin D metabolism and target genes in colon cancer cells.The Journal of steroid biochemistry and molecular biology · 2014Review
- Regulation of the calcium-sensing receptor expression by 1,25-dihydroxyvitamin D3, interleukin-6, and tumor necrosis factor alpha in colon cancer cells.The Journal of steroid biochemistry and molecular biology · 2014Review
- Sustained conditional knockdown reveals intracellular bone sialoprotein as essential for breast cancer skeletal metastasis.Oncotarget · 2014Article
- Egr-1 upregulates Siva-1 expression and induces cardiac fibroblast apoptosis.International journal of molecular sciences · 2014Article
- The transcription factor MEF2C negatively controls angiogenic sprouting of endothelial cells depending on oxygen.PloS one · 2014Article
- Egr-1 activation by cancer-derived extracellular vesicles promotes endothelial cell migration via ERK1/2 and JNK signaling pathways.PloS one · 2014Article
- Insulin inhibits lipolysis in adipocytes via the evolutionarily conserved mTORC1-Egr1-ATGL-mediated pathway.Molecular and cellular biology · 2013Article
- Early growth response 1 regulates glucose deprivation-induced necrosis.Oncology reports · 2013Article
- Article
- FOXO3 modulates endothelial gene expression and function by classical and alternative mechanisms.The Journal of biological chemistry · 2010Article
- Protective effect of carbon monoxide pre-conditioning on LPS-induced endothelial cell stress.Cell stress & chaperones · 2010Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
14 authors at 5 institutions in 3 countries.
Funding
Abstract
Transient induction of the transcription factor early growth response protein-1 (EGR-1) plays a pivotal role in the transcriptional response of endothelial cells to the angiogenic growth factors vascular endothelial growth factor (VEGF) and basic fibroblast growth factor (bFGF), which are produced by most tumors and are involved in the angiogenic switch. We report here that sustained expression of EGR-1 by recombinant adenoviruses in endothelial cells, however, leads to the specific induction of potent feedback inhibitory mechanisms, including strong up-regulation of transcriptional repressors, negative cell cycle check point effectors, proteins with established antiangiogenic activity, and several proapoptotic genes. Sustained EGR-1 expression consistently leads to an antiangiogenic state characterized by an altered responsiveness to VEGF and bFGF and a striking inhibition of sprouting and tubule formation in vitro. Furthermore, EGR-1-expressing viruses potently inhibit cell invasion and vessel formation in the murine Matrigel model and repress tumor growth in a murine fibrosarcoma model. We propose that gene therapy involving sustained EGR-1 expression may constitute a novel therapeutic principle in the treatment of cancer due to the simultaneous induction of multiple pathways of antiangiogenesis, growth arrest, and apoptosis induction in proliferating cells leading to preferential inhibition of angiogenesis and tumor growth.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.